APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mitogen Activated Protein Kinase 14

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mitogen Activated Protein Kinase 14 Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchMitogen Activated Protein Kinase 14 Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Mitogen Activated Protein Kinase 14 Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Mitogen Activated Protein Kinase 14 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mitogen Activated Protein Kinase 14 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Mitogen Activated Protein Kinase 14 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Mitogen Activated Protein Kinase 14 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mitogen Activated Protein Kinase 14 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mitogen Activated Protein Kinase 14 market include Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca Plc, Zocere, Inc., Toray Industries, Synovo GmbH, Chroma Therapeutics Limited, Chiesi Farmaceutici SpA and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mitogen Activated Protein Kinase 14 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mitogen Activated Protein Kinase 14 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mitogen Activated Protein Kinase 14 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mitogen Activated Protein Kinase 14 market size, projected growth trends, production technologies, key applications, and end-use industries.

Mitogen Activated Protein Kinase 14 Segment by Company

Eli Lilly and Company

GlaxoSmithKline Plc

AstraZeneca Plc

Zocere, Inc.

Toray Industries

Synovo GmbH

Chroma Therapeutics Limited

Chiesi Farmaceutici SpA

Astellas Pharma Inc.

Array BioPharma Inc.

Mitogen Activated Protein Kinase 14 Segment by Type

Ralimetinib Mesylate

Neflamapimod

Losmapimod

CHF-6297

Others

Mitogen Activated Protein Kinase 14 Segment by Application

Gastric Cancer

Epithelial Ovarian Cancer

Chronic Inflammation

Ulcerative Colitis

Others

Mitogen Activated Protein Kinase 14 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Mitogen Activated Protein Kinase 14 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mitogen Activated Protein Kinase 14 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mitogen Activated Protein Kinase 14 significant trends, drivers, influence factors in global and regions.

6. To analyze Mitogen Activated Protein Kinase 14 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mitogen Activated Protein Kinase 14 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mitogen Activated Protein Kinase 14 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mitogen Activated Protein Kinase 14.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mitogen Activated Protein Kinase 14 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mitogen Activated Protein Kinase 14 industry.

Chapter 3: Detailed analysis of Mitogen Activated Protein Kinase 14 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mitogen Activated Protein Kinase 14 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mitogen Activated Protein Kinase 14 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mitogen Activated Protein Kinase 14 Industry Trends Table 2. Mitogen Activated Protein Kinase 14 Industry Drivers Table 3. Mitogen Activated Protein Kinase 14 Industry Opportunities and Challenges Table 4. Mitogen Activated Protein Kinase 14 Industry Restraints Table 5. Global Mitogen Activated Protein Kinase 14 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mitogen Activated Protein Kinase 14 Revenue Share by Company (2021-2026) Table 7. Global Mitogen Activated Protein Kinase 14 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Company (2021-2026) Table 9. Global Mitogen Activated Protein Kinase 14 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Mitogen Activated Protein Kinase 14 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mitogen Activated Protein Kinase 14 Key Company Manufacturing Base & Headquarters Table 12. Global Mitogen Activated Protein Kinase 14 Company, Product Type & Application Table 13. Global Mitogen Activated Protein Kinase 14 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mitogen Activated Protein Kinase 14 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ralimetinib Mesylate Table 18. Significant Companies of Neflamapimod Table 19. Significant Companies of Losmapimod Table 20. Significant Companies of CHF-6297 Table 21. Significant Companies of Others Table 22. Global Mitogen Activated Protein Kinase 14 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Mitogen Activated Protein Kinase 14 Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Mitogen Activated Protein Kinase 14 Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Type (2021-2026) Table 26. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Type (2027-2032) Table 27. Global Mitogen Activated Protein Kinase 14 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Mitogen Activated Protein Kinase 14 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Mitogen Activated Protein Kinase 14 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Type (2021-2026) Table 31. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Gastric Cancer Table 33. Significant Companies of Epithelial Ovarian Cancer Table 34. Significant Companies of Chronic Inflammation Table 35. Significant Companies of Ulcerative Colitis Table 36. Significant Companies of Others Table 37. Global Mitogen Activated Protein Kinase 14 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Mitogen Activated Protein Kinase 14 Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Mitogen Activated Protein Kinase 14 Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Application (2021-2026) Table 41. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Application (2027-2032) Table 42. Global Mitogen Activated Protein Kinase 14 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Mitogen Activated Protein Kinase 14 Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Mitogen Activated Protein Kinase 14 Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Application (2021-2026) Table 46. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Application (2027-2032) Table 47. Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Mitogen Activated Protein Kinase 14 Sales by Region (2021-2026) & (K Units) Table 49. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Region (2021-2026) Table 50. Global Mitogen Activated Protein Kinase 14 Sales by Region (2027-2032) & (K Units) Table 51. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Region (2027-2032) Table 52. Global Mitogen Activated Protein Kinase 14 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Mitogen Activated Protein Kinase 14 Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Region (2021-2026) Table 55. Global Mitogen Activated Protein Kinase 14 Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Region (2027-2032) Table 57. Global Mitogen Activated Protein Kinase 14 Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Mitogen Activated Protein Kinase 14 Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Mitogen Activated Protein Kinase 14 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Mitogen Activated Protein Kinase 14 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026) & (K Units) Table 62. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2021-2026) Table 63. Global Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032) & (K Units) Table 64. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Country (2027-2032) Table 65. Global Mitogen Activated Protein Kinase 14 Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Mitogen Activated Protein Kinase 14 Sales Value Market Share by Country (2021-2026) Table 67. Global Mitogen Activated Protein Kinase 14 Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Mitogen Activated Protein Kinase 14 Sales Value Market Share by Country (2027-2032) Table 69. Eli Lilly and Company Company Information Table 70. Eli Lilly and Company Business Overview Table 71. Eli Lilly and Company Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Eli Lilly and Company Mitogen Activated Protein Kinase 14 Product Portfolio Table 73. Eli Lilly and Company Recent Development Table 74. GlaxoSmithKline Plc Company Information Table 75. GlaxoSmithKline Plc Business Overview Table 76. GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Product Portfolio Table 78. GlaxoSmithKline Plc Recent Development Table 79. AstraZeneca Plc Company Information Table 80. AstraZeneca Plc Business Overview Table 81. AstraZeneca Plc Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. AstraZeneca Plc Mitogen Activated Protein Kinase 14 Product Portfolio Table 83. AstraZeneca Plc Recent Development Table 84. Zocere, Inc. Company Information Table 85. Zocere, Inc. Business Overview Table 86. Zocere, Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Zocere, Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 88. Zocere, Inc. Recent Development Table 89. Toray Industries Company Information Table 90. Toray Industries Business Overview Table 91. Toray Industries Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Toray Industries Mitogen Activated Protein Kinase 14 Product Portfolio Table 93. Toray Industries Recent Development Table 94. Synovo GmbH Company Information Table 95. Synovo GmbH Business Overview Table 96. Synovo GmbH Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Synovo GmbH Mitogen Activated Protein Kinase 14 Product Portfolio Table 98. Synovo GmbH Recent Development Table 99. Chroma Therapeutics Limited Company Information Table 100. Chroma Therapeutics Limited Business Overview Table 101. Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Product Portfolio Table 103. Chroma Therapeutics Limited Recent Development Table 104. Chiesi Farmaceutici SpA Company Information Table 105. Chiesi Farmaceutici SpA Business Overview Table 106. Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Product Portfolio Table 108. Chiesi Farmaceutici SpA Recent Development Table 109. Astellas Pharma Inc. Company Information Table 110. Astellas Pharma Inc. Business Overview Table 111. Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 113. Astellas Pharma Inc. Recent Development Table 114. Array BioPharma Inc. Company Information Table 115. Array BioPharma Inc. Business Overview Table 116. Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio Table 118. Array BioPharma Inc. Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Mitogen Activated Protein Kinase 14 Distributors List Table 122. Mitogen Activated Protein Kinase 14 Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Mitogen Activated Protein Kinase 14 Product Image Figure 2. Global Mitogen Activated Protein Kinase 14 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mitogen Activated Protein Kinase 14 Sales (2021-2032) & (K Units) Figure 5. Global Mitogen Activated Protein Kinase 14 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Mitogen Activated Protein Kinase 14 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ralimetinib Mesylate Image Figure 10. Neflamapimod Image Figure 11. Losmapimod Image Figure 12. CHF-6297 Image Figure 13. Others Image Figure 14. Global Mitogen Activated Protein Kinase 14 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Mitogen Activated Protein Kinase 14 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Type (2021-2032) Figure 17. Global Mitogen Activated Protein Kinase 14 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Mitogen Activated Protein Kinase 14 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Type (2021-2032) Figure 20. Gastric Cancer Image Figure 21. Epithelial Ovarian Cancer Image Figure 22. Chronic Inflammation Image Figure 23. Ulcerative Colitis Image Figure 24. Others Image Figure 25. Global Mitogen Activated Protein Kinase 14 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Mitogen Activated Protein Kinase 14 Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Application (2021-2032) Figure 28. Global Mitogen Activated Protein Kinase 14 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Mitogen Activated Protein Kinase 14 Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Application (2021-2032) Figure 31. Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Mitogen Activated Protein Kinase 14 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Mitogen Activated Protein Kinase 14 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Mitogen Activated Protein Kinase 14 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 36. North America Mitogen Activated Protein Kinase 14 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Mitogen Activated Protein Kinase 14 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Mitogen Activated Protein Kinase 14 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 42. South America Mitogen Activated Protein Kinase 14 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Mitogen Activated Protein Kinase 14 Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Mitogen Activated Protein Kinase 14 Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Mitogen Activated Protein Kinase 14 Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Mitogen Activated Protein Kinase 14 Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Ralimetinib Mesylate
  • Neflamapimod
  • Losmapimod
  • CHF-6297
  • Others
Applications
  • Gastric Cancer
  • Epithelial Ovarian Cancer
  • Chronic Inflammation
  • Ulcerative Colitis
  • Others
Companies covered
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Zocere, Inc.
  • Toray Industries
  • Synovo GmbH
  • Chroma Therapeutics Limited
  • Chiesi Farmaceutici SpA
  • Astellas Pharma Inc.
  • Array BioPharma Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  4. 1.2.2 Global Mitogen Activated Protein Kinase 14 Sales Volume (2021-2032)
  5. 1.2.3 Global Mitogen Activated Protein Kinase 14 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mitogen Activated Protein Kinase 14 Market Dynamics
  1. 2.1 Mitogen Activated Protein Kinase 14 Industry Trends
  2. 2.2 Mitogen Activated Protein Kinase 14 Industry Drivers
  3. 2.3 Mitogen Activated Protein Kinase 14 Industry Opportunities and Challenges
  4. 2.4 Mitogen Activated Protein Kinase 14 Industry Restraints
3 Mitogen Activated Protein Kinase 14 Market by Company
  1. 3.1 Global Mitogen Activated Protein Kinase 14 Company Revenue Ranking in 2025
  2. 3.2 Global Mitogen Activated Protein Kinase 14 Revenue by Company (2021-2026)
  3. 3.3 Global Mitogen Activated Protein Kinase 14 Sales Volume by Company (2021-2026)
  4. 3.4 Global Mitogen Activated Protein Kinase 14 Average Price by Company (2021-2026)
  5. 3.5 Global Mitogen Activated Protein Kinase 14 Company Ranking (2024-2026)
  6. 3.6 Global Mitogen Activated Protein Kinase 14 Company Manufacturing Base and Headquarters
  7. 3.7 Global Mitogen Activated Protein Kinase 14 Company Product Type and Application
  8. 3.8 Global Mitogen Activated Protein Kinase 14 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mitogen Activated Protein Kinase 14 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mitogen Activated Protein Kinase 14 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mitogen Activated Protein Kinase 14 Market by Type
  1. 4.1 Mitogen Activated Protein Kinase 14 Type Introduction
  2. 4.1.1 Ralimetinib Mesylate
  3. 4.1.2 Neflamapimod
  4. 4.1.3 Losmapimod
  5. 4.1.4 CHF-6297
  6. 4.1.5 Others
  7. 4.2 Global Mitogen Activated Protein Kinase 14 Sales Volume by Type
  8. 4.2.1 Global Mitogen Activated Protein Kinase 14 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Mitogen Activated Protein Kinase 14 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Mitogen Activated Protein Kinase 14 Sales Value by Type
  12. 4.3.1 Global Mitogen Activated Protein Kinase 14 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Mitogen Activated Protein Kinase 14 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Mitogen Activated Protein Kinase 14 Sales Value Share by Type (2021-2032)
5 Mitogen Activated Protein Kinase 14 Market by Application
  1. 5.1 Mitogen Activated Protein Kinase 14 Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Epithelial Ovarian Cancer
  4. 5.1.3 Chronic Inflammation
  5. 5.1.4 Ulcerative Colitis
  6. 5.1.5 Others
  7. 5.2 Global Mitogen Activated Protein Kinase 14 Sales Volume by Application
  8. 5.2.1 Global Mitogen Activated Protein Kinase 14 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Mitogen Activated Protein Kinase 14 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Mitogen Activated Protein Kinase 14 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Mitogen Activated Protein Kinase 14 Sales Value by Application
  12. 5.3.1 Global Mitogen Activated Protein Kinase 14 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Mitogen Activated Protein Kinase 14 Sales Value by Application (2021-2032)
  14. 5.3.3 Global Mitogen Activated Protein Kinase 14 Sales Value Share by Application (2021-2032)
6 Mitogen Activated Protein Kinase 14 Regional Sales and Value Analysis
  1. 6.1 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mitogen Activated Protein Kinase 14 Sales by Region (2021-2032)
  3. 6.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021-2026
  4. 6.2.2 Global Mitogen Activated Protein Kinase 14 Sales by Region (2027-2032)
  5. 6.3 Global Mitogen Activated Protein Kinase 14 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mitogen Activated Protein Kinase 14 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mitogen Activated Protein Kinase 14 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mitogen Activated Protein Kinase 14 Sales Value by Region (2027-2032)
  9. 6.5 Global Mitogen Activated Protein Kinase 14 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  12. 6.6.2 North America Mitogen Activated Protein Kinase 14 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  15. 6.7.2 Europe Mitogen Activated Protein Kinase 14 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mitogen Activated Protein Kinase 14 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  21. 6.9.2 South America Mitogen Activated Protein Kinase 14 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mitogen Activated Protein Kinase 14 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mitogen Activated Protein Kinase 14 Sales Value Share by Country, 2025 VS 2032
7 Mitogen Activated Protein Kinase 14 Country-level Sales and Value Analysis
  1. 7.1 Global Mitogen Activated Protein Kinase 14 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mitogen Activated Protein Kinase 14 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
  4. 7.3.1 Global Mitogen Activated Protein Kinase 14 Sales by Country (2021-2026)
  5. 7.3.2 Global Mitogen Activated Protein Kinase 14 Sales by Country (2027-2032)
  6. 7.4 Global Mitogen Activated Protein Kinase 14 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mitogen Activated Protein Kinase 14 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mitogen Activated Protein Kinase 14 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mitogen Activated Protein Kinase 14 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mitogen Activated Protein Kinase 14 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mitogen Activated Protein Kinase 14 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Zocere, Inc.
  20. 8.4.1 Zocere, Inc. Company Information
  21. 8.4.2 Zocere, Inc. Business Overview
  22. 8.4.3 Zocere, Inc. Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zocere, Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  24. 8.4.5 Zocere, Inc. Recent Developments
  25. 8.5 Toray Industries
  26. 8.5.1 Toray Industries Company Information
  27. 8.5.2 Toray Industries Business Overview
  28. 8.5.3 Toray Industries Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Toray Industries Mitogen Activated Protein Kinase 14 Product Portfolio
  30. 8.5.5 Toray Industries Recent Developments
  31. 8.6 Synovo GmbH
  32. 8.6.1 Synovo GmbH Company Information
  33. 8.6.2 Synovo GmbH Business Overview
  34. 8.6.3 Synovo GmbH Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Synovo GmbH Mitogen Activated Protein Kinase 14 Product Portfolio
  36. 8.6.5 Synovo GmbH Recent Developments
  37. 8.7 Chroma Therapeutics Limited
  38. 8.7.1 Chroma Therapeutics Limited Company Information
  39. 8.7.2 Chroma Therapeutics Limited Business Overview
  40. 8.7.3 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Product Portfolio
  42. 8.7.5 Chroma Therapeutics Limited Recent Developments
  43. 8.8 Chiesi Farmaceutici SpA
  44. 8.8.1 Chiesi Farmaceutici SpA Company Information
  45. 8.8.2 Chiesi Farmaceutici SpA Business Overview
  46. 8.8.3 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Product Portfolio
  48. 8.8.5 Chiesi Farmaceutici SpA Recent Developments
  49. 8.9 Astellas Pharma Inc.
  50. 8.9.1 Astellas Pharma Inc. Company Information
  51. 8.9.2 Astellas Pharma Inc. Business Overview
  52. 8.9.3 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  54. 8.9.5 Astellas Pharma Inc. Recent Developments
  55. 8.10 Array BioPharma Inc.
  56. 8.10.1 Array BioPharma Inc. Company Information
  57. 8.10.2 Array BioPharma Inc. Business Overview
  58. 8.10.3 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
  60. 8.10.5 Array BioPharma Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mitogen Activated Protein Kinase 14 Value Chain Analysis
  2. 9.1.1 Mitogen Activated Protein Kinase 14 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mitogen Activated Protein Kinase 14 Sales Mode & Process
  6. 9.2 Mitogen Activated Protein Kinase 14 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mitogen Activated Protein Kinase 14 Distributors
  9. 9.2.3 Mitogen Activated Protein Kinase 14 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst